

Boletín de Vigilancia Tecnológica N°3

Vencer al Covid-19: Vigilancia de los avances globales en CyT

Abril 2020

PRESENTACIÓN

El equipo de IALE Tecnología, ha querido empatizar con la difícil situación que estamos viviendo poniendo sus capacidades al servicio de todos quienes quieran recoger esta valiosa síntesis de información para sumar soluciones que ayuden a Vencer al COVID-19.

Una mirada global de los esfuerzos en Ciencia y Tecnología, desde la publicaciones científicas, los ensayos clínicos, las startups, y más....

Esta divulgación nos debe ayudar a valorar las muchas iniciativas que cada día aparecen en distintos lugares del mundo y que son de gran valor para avanzar en la búsqueda de una solución.

Atentamente,

Equipo IALE Tecnología

ÍNDICE

PUBLICACIONES CIENTÍFICAS

Cómo el grupo sanguíneo A podría ser un riesgo y el grupo sanguíneo O estar protegido...	2
Promesas y riesgos de las pruebas de anticuerpos para COVID-19	2
Tendencias de la infección por SARS-Cov-2 en 67 países: papel de la zona climática, t...	3
¿Existe evidencia de que la vacuna BCG tiene efectos protectores no específicos para ...	3
Inhibidores del sistema renina-angiotensina-aldosterona en pacientes con Covid-19	4
El bloqueo de la autofagia inducida por fármacos con cloroquina en células de cáncer ...	5
El poderoso sistema inmunitario contra el potente COVID-19: una hipótesis	6
SARS - CoV -2: razones de epidemiología de casos de enfermedades graves y enfoque ter...	7
Predicción de la estructura de la proteasa tipo 3C (3CLpro) SARS-CoV-2 (2019-nCoV): e...	7
Modelado y pronóstico de la propagación de epidemias: el caso de Covid-19 y futuros c...	8
Desafíos del manejo de los portadores asintomáticos de SARS-CoV-2	9
Detección de SARS-CoV-2 basada en Cas12-CRISPR	9
Infección por SARS-Cov-2: respuesta del sistema inmunitario humano y posibles implica...	10
Dinámica temporal en la eliminación viral y la transmisibilidad de COVID-19	10
La extensión geográfica de COVID-19 se correlaciona con la estructura de las redes so...	11
El fármaco Ivermectin aprobado por el FDA inhibe la replicación del SARS-CoV-2 in vit...	12
El nivel de IL-6 predice insuficiencia respiratoria en pacientes hospitalizados sinto...	12

ENSAYOS CLÍNICOS

Eficacia de Tocilizumab en pacientes con COVID-19	13
Ensayo de generación de trombina modificada con trombomodulina (TGA-TM) en pacientes ...	13
Impacto de los inhibidores de la proteasa a largo plazo en pacientes que viven con VI...	14
Características y resultados de pacientes hospitalizados con COVID-19 en España	14
Evaluación de la actividad y la seguridad de dos regímenes de dosis bajas de Selinexo...	15
Tratamiento con corticosteroides inhalados de pacientes con COVID19 con neumonía	15
Plasma convaleciente en pacientes de la UCI con insuficiencia respiratoria inducida p...	15
Diagnóstico pulmonar de Coronavirus (COVID-19) con ultrasonido	16
Novedosa terapia celular adoptiva con TCells específicos de SARS-CoV-2 en pacientes c...	17
Defibrotida como prevención y tratamiento del distrés respiratorio y el síndrome de l...	17
Actualización evaluación FIND: ensayos inmunológicos de SARS-CoV-2	17
Predictores NIV y CPAP en fallas respiratorias asociadas a COVID-19	18
Plasma convaleciente para pacientes con COVID-19: un estudio piloto (CP-COVID-19)	18

PROYECTOS

La NASA desarrolla prototipo de Ventilador para el COVID-19 en 37 días	20
Científicos de University of Eastern de Finlandia están desarrollando una vacuna nasa...	20

ÍNDICE

El Hospital de Sant Pau, QEV Technologies, Nissan y Eurecat desarrollan un respirador...	21
Investigadores de Stanford lideran los esfuerzos para fabricar ventiladores de respue...	21
El MIT desarrolla una caja inalámbrica para detectar el movimiento y la respiración d...	22
El Departamento de Salud financia dos proyectos de IrsiCaixa para la investigación co...	23
Coordinación del programa de pruebas masivas COVID-19 (Programa Orfeu) de la Generali...	24
ISGlobal y el Hospital Clínic inician dos nuevos estudios para combatir la COVID-19	24

STARTUPS

SunCrafter desarrolla un desinfectante de manos por luz ultravioleta que funciona con...	26
Un estudio en Liechtenstein de científicos y emprendedores usa el brazalete de la Sta...	26
Emerge, una aplicación de blockchain que ayuda a rastrear los casos de Covid-19	27
La solución de telemedicina de Zerintia mejora el seguimiento médico de mayores y enf...	28
La startup israelita Diagnostic Robotics desarrolla plataforma con IA para monitoriza...	29
Coronavirus Las startups impulsadas por Juan Roig reorientan sus negocios para luch...	30
La Islandesa Sidekick crea una solución para el cuidado remoto de los pacientes de CO...	31
¿Puede su teléfono inteligente detectar signos tempranos de infección por coronavirus...	32
Corona-tracker de Velmio	32

NOTICIAS

La vacuna del COVID-19 de la Universidad de Oxford comienza la etapa de pruebas en hu...	33
La farmacéutica Roche desarrolla la prueba de detección de anticuerpos COVID-19	33
El CSIC lanza un estudio genético para identificar el riesgo individual de desarrolla...	34
Científicos de todo el mundo trabajan en 115 posibles vacunas para el COVID-19	34
Grifols dice que las inmunoglobinas hiperinmunes contra el coronavirus podrían estar ...	35
¿Tienen las personas vacunadas con BCG alguna ventaja de inmunidad sobre las personas...	36
SOM Biotech anuncia la confirmación in vitro de tres candidatos a fármacos para COVID...	37
IVI, INOVIO y KNIH se asociarán con CEPI en la fase 1/2 del ensayo clínico de la vacu...	38
Moderna: Timeline de nuestra respuesta a día 16 de 2020	38
Sanofi y GSK unirán fuerzas en una colaboración de vacunas sin precedentes para lucha...	39
Vencer al virus: más de 160 candidatos a fármacos y vacunas COVID-19 en desarrollo	39
Carta abierta del CEO de Gilead	40
Michelin y otras compañías en la región francesa de Auvergne-Rhône-Alpes se unen para...	40

Vencer al Covid-19

PUBLICACIONES CIENTÍFICAS

Cómo el grupo sanguíneo A podría ser un riesgo y el grupo sanguíneo O estar protegido de las infecciones por coronavirus (COVID-19) (cómo el virus invade al ser humano a través de los carbohidratos del grupo sanguíneo)

PUBLICACIONES CIENTÍFICAS | Publicada el 23/04/2020

When according to the numbers of Wikipedia (although they are disputed) in countries like Chile, Ecuador, Colombia, Simbabwe and Mexico 59 to 85 percent of the people have blood group O and these countries officially publish extremely low COVID-19 cases and death rates per 1 million inhabitants, this may not alone result from insufficient investigations but might suggest a lower susceptibility of blood group O to the disease. The molecular biology of a virus infection pathogenesis determines the genetic target and the human phenotype-determining enzymes decide about the difference between infection and disease.

[Más información aquí.](#)

Promesas y riesgos de las pruebas de anticuerpos para COVID-19

PUBLICACIONES CIENTÍFICAS | Publicada el 23/04/2020

No deben utilizarse para diagnosticar casos activos Promesas y riesgos de las pruebas de anticuerpos para COVID-19. Las pruebas serológicas podrían utilizarse para comprobar el estado de la inmunidad luego de la recuperación e incluso para devolver a las personas inmunizadas a la vida normal

[Más información aquí.](#)



Scatter plot showing the relationship between the number of days to reach the first 100 cases of COVID-19 (X-axis) and the number of cases per million (Y-axis). The X-axis ranges from 0 to 60, and the Y-axis is on a logarithmic scale from 1 to 10. A negative correlation is shown with a dashed regression line and the text $r = -0.71, p = 4.4E-19$. Data points are labeled with country codes.

PUBLICACIONES CIENTÍFICAS | Publicada el 23/04/2020

Summary Objective. To analyze the role of temperature, humidity, date of first case diagnosed (DFC) and the behavior of the growth-curve of cumulative frequency (CF) [number of days to rise (DCS) and reach the first 100 cases (D100), and the difference between them (DD)] with the doubling time (Td) of Covid-19 cases in 67 countries grouped by climate zone. **Design.** Retrospective incident case study. **Setting.** WHO based register of cumulative incidence of Covid-19 cases. **Participants.** 1,706,914 subjects diagnosed between 12-29-2019 and 4-15-2020. **Exposures.** SARS-Cov-2 virus, ambient humidity, temperature and climate areas (temperate, tropical/subtropical).

Más información aquí.

Vencer al Covid-19


¿Existe evidencia de que la vacuna BCG tiene efectos protectores no específicos para las infecciones por COVID 19 o es una ilusión creada por la falta de pruebas?

PUBLICACIONES CIENTÍFICAS | Publicada el 23/04/2020

The goal of this paper is to showcase that the COVID-19 disease pattern is evolving and to study the relationship between mandatory BCG policy and caseload/million or death/per million. We analyze seven recent publications on the impact of BCG vaccinations on the development of COVID19 illness and extend presented findings using the latest data from April 10, 2020. We analyze data from 98 countries and we extend existing models by adding the dimension of COVID-19-related testing conducted by the analyzed countries. Similarly to prior studies, we find that COVID-19 attributable case and death incidences across countries share a relationship with the BCG vaccination inclusion in the national immunization program of a country when testing is not taken into consideration. However, this relationship vanishes when we add the dimension of testing.

[Más información aquí.](#)

Vencer al Covid-19



Inhibidores del sistema renina-angiotensina-aldosterona en pacientes con Covid-19

PUBLICACIONES CIENTÍFICAS | Publicada el 22/04/2020

The renin–angiotensin–aldosterone system (RAAS) is an elegant cascade of vasoactive peptides that orchestrate key processes in human physiology. Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and SARS-CoV-2, which have been responsible for the SARS epidemic in 2002 to 2004 and for the more recent coronavirus disease 2019 (Covid-19) pandemic, respectively, interface with the RAAS through angiotensin-converting enzyme 2 (ACE2), an enzyme that physiologically counters RAAS activation but also functions as a receptor for both SARS viruses.^{1,2} The interaction between the SARS viruses and ACE2 has been proposed as a potential factor in their infectivity,^{3,4} and there are concerns about the use of RAAS inhibitors that may alter ACE2 and whether variation in ACE2 expression may be in part responsible for disease virulence in the ongoing Covid-19 pandemic.

Más información aquí.

Vencer al Covid-19

El bloqueo de la autofagia inducida por fármacos con cloroquina en células de cáncer de colon HCT-116 mejora la maduración de DC y las respuestas de células T inducidas por lisado de células tumorales

PUBLICACIONES CIENTÍFICAS | Publicada el 22/04/2020

Autophagy is an important mechanism for tumor escape, allowing tumor cells to recover from the damage induced by chemotherapy, radiation therapy, and immunotherapy and contributing to the development of resistance. The pharmacological inhibition of autophagy contributes to increase the efficacy of antineoplastic agents. Exposing tumor cells to low concentrations of select autophagy-inducing antineoplastic agents increases their immunogenicity and enhances their ability to stimulate dendritic cell (DC) maturation. We tested whether the application of an autophagy-inhibiting agent, chloroquine (CQ), in combination with low concentrations of 5-fluorouracil (5-FU) increases the ability of tumor cells to induce DC maturation. DCs sensitized with the lysate of HCT-116 cells previously exposed to such a combination enhanced the DC maturation/activation ability.

[Más información aquí.](#)

El poderoso sistema inmunitario contra el potente COVID-19: una hipótesis

PUBLICACIONES CIENTÍFICAS | Publicada el 22/04/2020

On March 11, 2020, the World Health Organization declared the coronavirus outbreak a pandemic. Since December 2019, the world has experienced an outbreak of coronavirus disease 2019 (COVID-19). Epidemiology, risk factors, and clinical characteristics of patients with COVID-19 have been reported but the factors affecting the immune system against COVID-19 have not been well described. In this article, we provide a novel hypothesis to describe how an increase in cellular adenosine triphosphate (c-ATP) can potentially improve the efficiency of innate and adaptive immune systems to either prevent and fight off COVID-19.

[Más información aquí.](#)

Vencer al Covid-19


SARS - CoV -2: razones de epidemiología de casos de enfermedades graves y enfoque terapéutico utilizando vacuna trivalente (tétanos, difteria y tos ferina)

PUBLICACIONES CIENTÍFICAS | Publicada el 22/04/2020

The novel coronavirus COVID-19 follows transmission route and clinical presentation of all community-acquired coronaviruses. Instead, the rate of transmission is significative higher, with a faster spread of the virus responsible of the worldwide outbreak and a significative higher mortality rate due to the development of a severe lung injury. Most noteworthy is the distribution of death rate among age groups. Children and younger people are almost protected from severe clinical presentation. Possible explanation of this phenomenon could be the ability of past vaccinations (especially tetanic, diphtheria toxoids and inactivated bacteria as pertussis) to stimulate immune system and to generate a scattered immunity against non-self antigens in transit, as coronaviruses and other community-circulating viruses and make immune system readier to develop specific immunity against COVID-19.

Más información aquí.

Vencer al Covid-19



Predicción de la estructura de la proteasa tipo 3C (3CLpro) SARS-CoV-2 (2019-nCoV): examen virtual revela velpatasvir, ledipasvir y otros candidatos para la reutilización de fármacos

PUBLICACIONES CIENTÍFICAS | Publicada el 21/04/2020

We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart.

[Más información aquí.](#)

Modelado y pronóstico de la propagación de epidemias: el caso de Covid-19 y futuros casos

PUBLICACIONES CIENTÍFICAS | Publicada el 20/04/2020

The Covid-19 pandemic is the most significant global crisis since the Second World War. Exceeding the size and range of the repercussions of a World War, it has affected all the Countries of our planet. The health consequences of the pandemic are devastating. To date the number of Covid-19 deaths exceeds 75,000 and is unfortunately destined to exponentially grow in the coming weeks.

[Más información aquí.](#)

Vencer al Covid-19

Desafíos del manejo de los portadores asintomáticos de SARS-CoV-2

PUBLICACIONES CIENTÍFICAS | Publicada el 18/04/2020

After an outbreak in Wuhan, China, a growing number of countries are now suffering from an epidemic by SARS-CoV-2, which causes COVID-19. Undoubtedly, reports of the skyrocketing global spread of COVID-19 has shocked people globally, from Japan to the United States. Presently, the World Health Organization indicates that fatality due to COVID-19 is about 2%, inferring that many positive subjects may potentially overcome the illness with mild influenza-like symptoms and no need for hospitalization at intensive-care units. Because COVID-19 is completely new to the human immune system, many throughout the world are likely vulnerable to becoming sick after their initial exposure to SARSCoV-2. Besides hospitalized cases, many individuals are likely asymptomatic but potentially carry the virus. While our knowledge about carriers and their virus shedding is deficient, some studies modelling the viral transmission have considered the potential contribution of the asymptomatic carriers.


[Más información aquí.](#)

Detección de SARS-CoV-2 basada en Cas12-CRISPR

PUBLICACIONES CIENTÍFICAS | Publicada el 16/04/2020

An outbreak of betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 began in Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 infection, rapidly spread to produce a global pandemic. We report development of a rapid (<40min), easy-to-implement and accurate CRISPR-Cas12-based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated our method using contrived reference samples and clinical samples from patients in the United States, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections.

[Más información aquí.](#)



Vencer al Covid-19


Infección por SARS-Cov-2: respuesta del sistema inmunitario humano y posibles implicaciones para los test rápidos y tratamiento

PUBLICACIONES CIENTÍFICAS | Publicada el 16/04/2020

The new coronavirus outbreak is an ongoing pandemic that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The new coronavirus SARS-Cov-2 belongs to the subfamily of coronaviruses and shares 79.5% of the genetic sequence of SARS-CoV, the causative agent of the epidemic that started in 2002 and ended in 2004. Considering the clinical impact of the new outbreak, it is highly important to study the potential responses of the human immune system during the SARS-CoV-2 infection as well as the role of virus-specific T cells and by B-lymphocytes. Moreover, specific data on the production of IgG and IgM is crucial to allow the rapid identification of the infection. In this paper we also described the importance of sensitive and specific rapid test for SARS-CoV-2. Indeed, this test represents an important immunological tool aimed at identifying the precise phase of the infection in order to undertake a more appropriate pharmacological treatment.

Más información aquí.

Vencer al Covid-19



Dinámica temporal en la eliminación viral y la transmisibilidad de COVID-19

PUBLICACIONES CIENTÍFICAS | Publicada el 15/04/2020

We report temporal patterns of viral shedding in 94 patients with laboratory-confirmed COVID-19 and modeled COVID-19 infectiousness profiles from a separate sample of 77 infector–infectee transmission pairs. We observed the highest viral load in throat swabs at the time of symptom onset, and inferred that infectiousness peaked on or before symptom onset. We estimated that 44% (95% confidence interval, 25–69%) of secondary cases were infected during the index cases' presymptomatic stage, in settings with substantial household clustering, active case finding and quarantine outside the home. Disease control measures should be adjusted to account for probable substantial presymptomatic transmission.

[Más información aquí.](#)


La extensión geográfica de COVID-19 se correlaciona con la estructura de las redes sociales según Facebook

PUBLICACIONES CIENTÍFICAS | Publicada el 07/04/2020

We use anonymized and aggregated data from Facebook to show that areas with stronger social ties to two early COVID-19 "hotspots" (Westchester County, NY, in the U.S. and Lodi province in Italy) generally have more confirmed COVID-19 cases as of March 30, 2020. These relationships hold after controlling for geographic distance to the hotspots as well as for the income and population density of the regions. These results suggest that data from online social networks may prove useful to epidemiologists and others hoping to forecast the spread of communicable diseases such as COVID-19.

[Más información aquí.](#)

Vencer al Covid-19



El fármaco Ivermectin aprobado por el FDA inhibe la replicación del SARS-CoV-2 in vitro

PUBLICACIONES CIENTÍFICAS | Publicada el 03/04/2020

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.


[Más información aquí.](#)

El nivel de IL-6 predice insuficiencia respiratoria en pacientes hospitalizados sintomáticos con COVID-19

PUBLICACIONES CIENTÍFICAS | Publicada el 01/04/2020

The pandemic Coronavirus-disease 19 (COVID-19) is characterized by a heterogeneous clinical course. While most patients experience only mild symptoms, a relevant proportion develop severe disease progression with increasing hypoxia up to acute respiratory distress syndrome. The substantial number of patients with severe disease have strained intensive care capacities to an unprecedented level.

[Más información aquí.](#)



Vencer al Covid-19

ENSAYOS CLÍNICOS

Eficacia de Tocilizumab en pacientes con COVID-19

ENSAYOS CLÍNICOS | Publicada el 22/04/2020

Condition: SARS-CoV 2 Interventions: Drug: Tocilizumab; Drug: Placebos Sponsors: Massachusetts General Hospital; Genentech, Inc. Not yet recruiting. This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection and evidence of systemic inflammation. Participants will complete screening procedures, where inclusion and exclusion criteria will be evaluated. After screening, participants who meet all inclusion criteria and none of the exclusion criteria will be randomized 2:1 to tocilizumab or placebo. Participants will be followed for safety for 28 days after the last dose of study drug. We anticipate enrolling between 300 patients admitted to Massachusetts General Hospital (and additional Partners sites, after approval, including BWH, NSMC, and the NWH) into the trial.

[Más información aquí.](#)

Ensayo de generación de trombina modificada con trombomodulina (TGA-TM) en pacientes con infecciones críticas

ENSAYOS CLÍNICOS | Publicada el 22/04/2020

Conditions: Disseminated Intravascular Coagulation; Critical Illness; Sars-CoV2; Viral Infection; Coagulation Disorder, Blood; Covid19 Interventions: Diagnostic Test: Thrombin Generation Assay (TGA); Diagnostic Test: Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Sponsors: Medical University of Vienna; Medical Scientific Fund of the Mayor of Vienna Not yet recruiting

[Más información aquí.](#)

Vencer al Covid-19

Impacto de los inhibidores de la proteasa a largo plazo en pacientes que viven con VIH sobre la incidencia de COVID-19 (COVIP)

ENSAYOS CLÍNICOS | Publicada el 22/04/2020

Condition: HIV Patients Intervention: Other: No intervention Sponsors: Centre Hospitalier Intercommunal Creteil; Centre Hospitalier Intercommunal Villeneuve St Georges Not yet recruiting. The symptomatic management of COVID-19 infections is currently at the forefront. The therapeutic efficacy of certain molecules is being evaluated in studies, in vitro and in vivo, such as remdesivir, hydroxychloroquine / chloroquine, and lopinavir / ritonavir. The latter has been used in the treatment of HIV for many years, like other PIs such as darunavir and atazanavir. In France, around 11% of PLWHIV are treated with long-term PIs.

[Más información aquí.](#)

Características y resultados de pacientes hospitalizados con COVID-19 en España

ENSAYOS CLÍNICOS | Publicada el 21/04/2020

Condition: Covid19 Intervention: Sponsor: Fundacion SEIMC-GESIDA Active, not recruiting COVID-19@Spain is a retrospective cohort study of patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Ethics Committee for Research with Medicines of Hospital General Universitario Gregorio Marañón approved the study and waived informed consent for the collection of clinical data. Investigators from participating centers were asked to include the first consecutive hospitalized patients (up to 100) meeting the study criteria from the start of the epidemic until March 17, 2020.

[Más información aquí.](#)

Vencer al Covid-19

Evaluación de la actividad y la seguridad de dos regímenes de dosis bajas de Selinexor oral en participantes con COVID-19 moderado o severo

ENSAYOS CLÍNICOS | Publicada el 21/04/2020

Condition: Coronavirus Infection Intervention: Drug: Selinexor Sponsor: Karyopharm Therapeutics Inc Not yet recruiting. Participants will receive 40 milligram (mg) of selinexor as oral tablets on Days 1 and 3 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).

[Más información aquí.](#)

Tratamiento con corticosteroides inhalados de pacientes con COVID19 con neumonía

ENSAYOS CLÍNICOS | Publicada el 21/04/2020

Condition: Coronavirus Infection Intervention: Drug: Inhaled budesonide Sponsor: Sara Varea Not yet recruiting. Randomized, prospective, controlled open label clinical trial aimed at investigating if the addition of inhaled corticosteroids (budesonide) reduces treatment failure (defined as a composite variable by the initiation of treatment with high flow-O2 therapy, non-invasive or invasive ventilation, systemic steroids, use of biologics (anti IL-6 or anti IL-1) and/or death) according to hospital standard of care guidance) at day 15 after initiation of therapeutic intervention.

[Más información aquí.](#)

Vencer al Covid-19

Plasma convaleciente en pacientes de la UCI con insuficiencia respiratoria inducida por COVID-19

ENSAYOS CLÍNICOS | Publicada el 20/04/2020

Conditions: Covid-19; Sars-CoV2 Intervention: Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma Sponsors: Noah Merin; Johns Hopkins University; University of Pittsburgh Medical Center Not yet recruiting. This study will assess the feasibility of administering multiple doses of convalescent plasma (from people who have recovered from SARS-CoV-2) to Covid-19 positive patients in the Intensive Care Unit receiving mechanical ventilation. Donor plasma will not be obtained under this protocol, but all plasma used will follow FDA guidelines for Investigational COVID-19 Convalescent Plasma use. Patients may receive single or double plasma units infused on days 0, 3, and 6. This decision may be based on availability of blood plasma. The primary objective of this study is feasibility. Feasibility will be assessed based on the proportion of subjects who consent and receive at least one dose of convalescent plasma. The study will be declared 'feasible' if at least 80% of subjects who consent receive at least one dose.

[Más información aquí.](#)

Diagnóstico pulmonar de Coronavirus (COVID-19) con ultrasonido

ENSAYOS CLÍNICOS | Publicada el 17/04/2020

Condition: COVID-19 Intervention: Diagnostic Test: Lung ultrasound Sponsor: University Hospital Plymouth NHS Trust Not yet recruiting. This observational study is designed to assess whether focused lung ultrasound examination can improve the diagnosis of COVID-19 lung disease and/or make an alternative diagnosis at a patient's initial hospital presentation. For patients with confirmed COVID-19 the study will also assess whether surveillance lung ultrasound examination can predict clinical outcome over the course of their hospital admission.

[Más información aquí.](#)

Vencer al Covid-19

Novedosa terapia celular adoptiva con TCells específicos de SARS-CoV-2 en pacientes con COVID-19 grave

ENSAYOS CLÍNICOS | Publicada el 17/04/2020

Condition: COVID-19 Intervention: Other: Blood donation from convalescent donor Sponsors: KK Women's and Children's Hospital; Singapore General Hospital; National University Hospital, Singapore Recruiting. The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis is that SARS-CoV-2 specific T cells from convalescent donors who have recovered from COVID-19 can be manufactured expeditiously for the treatment of severe SARS-CoV-2 infections.

[Más información aquí.](#)

Defibrotida como prevención y tratamiento del distrés respiratorio y el síndrome de liberación de citocinas del Covid 19.

ENSAYOS CLÍNICOS | Publicada el 16/04/2020

Condition: COVID19 Interventions: Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days; Drug: Placebo 250 cc 24 hours continuous infusion for 15 days Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia Recruiting

[Más información aquí.](#)


Vencer al Covid-19

Actualización evaluación FIND: ensayos inmunológicos de SARS- CoV-2

ENSAYOS CLÍNICOS | Publicada el 13/04/2020

On 13 March 2020, FIND launched an expression of interest (EOI) process for test developers interested in having their immunoassays (manual ELISA, machine-based or lateral flow, rapid tests specific for SARS-CoV-2 antigen or antibodies) evaluated using a standardized, independent protocol. The EOI closed on 20 March 2020. Close to 100 immunoassay submissions were received, including 19 for antigen detection, and over 70 for antibody detection.

[Más información aquí.](#)



Predictores NIV y CPAP en fallas respiratorias asociadas a COVID-19

ENSAYOS CLÍNICOS | Publicada el 10/04/2020

Conditions: Respiratory Failure; Covid-19 Interventions: Other: Monitoring for aggravation; Other: Evaluate HACOR score effectivity in this patients Sponsor: Hospital General Universitario Morales Meseguer Recruiting. Evaluate HACOR score utility and efficacy in predicting NIV and/or CPAP failure in patients with COVID-19 associated respiratory failure. Propose adaptations to HACOR score based on the "state of art" of COVID-19

[Más información aquí.](#)

Vencer al Covid-19

Plasma convaleciente para pacientes con COVID-19: un estudio piloto (CP-COVID-19)

ENSAYOS CLÍNICOS | Publicada el 02/04/2020

Convalescent plasma (CP) has been used in recent years as an empirical treatment strategy when there is no vaccine or treatment available for infectious diseases. In the latest viral epidemics, such as the Ebola outbreak in West Africa in 2014, the World Health Organization issued a document outlining a protocol for the use of whole blood or plasma collected from patients who have recovered from the Ebola virus disease by transfusion to empirically treat local infectious outbreaks.

Más información aquí.

Vencer al Covid-19

PROYECTOS



La NASA desarrolla prototipo de Ventilador para el COVID-19 en 37 días

PROYECTOS | Publicada el 23/04/2020

A high-pressure ventilator designed by the agency's Jet Propulsion Laboratory for rapid production is being tested for use in medical centers. A new high-pressure ventilator developed by NASA engineers and tailored to treat coronavirus (COVID-19) patients passed a critical test Tuesday at the Icahn School of Medicine at Mount Sinai in New York, an epicenter of COVID-19 in the United States.

[Más información aquí.](#)


Científicos de University of Eastern de Finlandia están desarrollando una vacuna nasal contra COVID-19

PROYECTOS | Publicada el 21/04/2020

Academy Professor Seppo Ylä-Herttuala at the University of Eastern Finland is working together with scientists from the University of Helsinki to develop a COVID-19 vaccine that will make use of gene transfer technology that has been developed in Kuopio. The efficacy of the vaccine, developed in collaboration with Professor Kalle Saksela and Academy Professor Kari Alitalo, can possibly be tested already this autumn. The drug development process can move forward quickly, thanks to the scientists already having the required technology at hand. Professor Saksela's research group is in possession of the surface protein of the COVID-19 virus, which is what the human body will build immunity to.

[Más información aquí.](#)

Vencer al Covid-19



El Hospital de Sant Pau, QEV Technologies, Nissan y Eurecat desarrollan un respirador para ayudar al abastecimiento de los países emergentes

PROYECTOS | Publicada el 15/04/2020

El Hospital de Sant Pau, la ingeniería QEV Technologies, la compañía automovilística Nissan y el centro tecnológico Eurecat han desarrollado el respirador Q-Vent para su utilización en las UCIs hospitalarias para paliar la falta de equipos generada por COVID-19 en todo el mundo, cuyo diseño está pensado para contribuir al abastecimiento de los países emergentes, dadas sus prestaciones a nivel de accesibilidad, flexibilidad y fiabilidad.

Más información aquí.

Vencer al Covid-19

Investigadores de Stanford lideran los esfuerzos para fabricar ventiladores de respuesta rápida

PROYECTOS | Publicada el 15/04/2020



An effort to design and build simplified ventilators for patients with severe cases of COVID-19 is being led by researchers at Stanford. A rendering of the ventilator being designed and built by researchers at Stanford Medicine, the Stanford School of Engineering, the Chan Zuckerberg Biohub and 219 Design. In normal times, David Camarillo, PhD, associate professor of bioengineering at Stanford, researches ways to prevent concussions. In the thick of the COVID-19 crisis, however, he's put aside that effort and taken on a new project: building ventilators, with the support of the Chan Zuckerberg Biohub.

Más información aquí.

Vencer al Covid-19



El MIT desarrolla una caja inalámbrica para detectar el movimiento y la respiración de los pacientes con COVID-19 en casa

PROYECTOS | Publicada el 14/04/2020

The COVID-19 pandemic has presented an unprecedented challenge for healthcare workers. Among the major challenges are social distancing issues, which have required novel approaches to diagnosing and treating illness. For many who have already tested positive, home stays are the best option to avoid an already massively overtaxed hospital system in many areas and to avoid further infecting others. The question, then, is how doctors and nurses can continue to provide treatment remotely with the pronounced limitations of telemedicine.

[Más información aquí.](#)

El Departamento de Salud financia dos proyectos de IrsiCaixa para la investigación contra la COVID-19

PROYECTOS | Publicada el 08/04/2020

IrsiCaixa lidera dos proyectos que se centran en el desarrollo de anticuerpos y una vacuna contra el coronavirus respectivamente y participa en un tercer proyecto que busca marcadores de progresión de la COVID-19.

[Más información aquí.](#)



Vencer al Covid-19



Coordinación del programa de pruebas masivas COVID-19 (Programa Orfeu) de la Generalitat de Catalunya.

PROYECTOS | Publicada el 04/04/2020

The Centre for Genomic Regulation (CRG) is coordinating a task force with the Institute for Research in Biomedicine (IRB Barcelona) and the Institute for Bioengineering of Catalonia (IBEC), as requested by Government of Catalonia, to set up mass testing for citizens to stop the spread of the new coronavirus outbreak. There are two mass testing sites – one coordinated by the CRG at its labs at the Barcelona Biomedical Research Park (PRBB) and another at the Parc Científic de Barcelona, jointly coordinated by IRB Barcelona, IBEC and the Centro Nacional de Análisis Genómico (CNAG-CRG), part of the CRG. The project, codenamed Programa Orfeu by the Generalitat de Catalunya, aims to run a total of 170 thousand tests in its first phase, which will last between April and the end of May.

[Más información aquí.](#)

Vencer al Covid-19



ISGlobal y el Hospital Clínic inician dos nuevos estudios para combatir la COVID-19

PROYECTOS | Publicada el 04/04/2020

Los estudios de tratamiento profiláctico y serología se están llevando a cabo con personal sanitario en el Hospital Clínic de Barcelona. Uno de los colectivos de más riesgo para la infección por SARS-CoV-2 es el personal sanitario, que al mismo tiempo es el pilar para la asistencia clínica de la población en general. Con el fin de proteger mejor a dicho colectivo, el Instituto de Salud Global de Barcelona (ISGlobal), centro impulsado por la Fundación "la Caixa", y el Hospital Clínic, hospital de referencia para el diagnóstico y tratamiento de COVID-19 en Cataluña y España, han lanzado dos nuevos estudios: uno para evaluar la eficacia de un tratamiento preventivo en personal sanitario particularmente expuesto y otro para conocer la prevalencia de la infección por SARS-CoV-2 en personal sanitario.

[Más información aquí.](#)

Vencer al Covid-19


STARTUPS

SunCrafter desarrolla un desinfectante de manos por luz ultravioleta que funciona con energía fotovoltaica y gana el hackathon Covid-19

STARTUPS | Publicada el 17/04/2020

An ESA-backed hackathon raised the idea of turning end-of-life PV modules into hand sanitizers. The team that won the hackathon is now working to rapidly roll out the solution at scale to contain the Covid-19 spread. The UV light kills the germs, but does not harm skin or eyes, the inventors claim.

Más información aquí.




Vencer al Covid-19

Un estudio en Liechtenstein de científicos y emprendedores usa el brazalete de la Startup Ava para combatir la pandemia del coronavirus

STARTUPS | Publicada el 15/04/2020

A consortium led by Liechtenstein scientists and entrepreneurs Professor Dr. Lorenz Risch and Dr. Martin Risch has just launched a scientific study aimed at combating the coronavirus: the COVI-GAPP study. Around 2,000 individuals in Liechtenstein are taking part. The aim is to see whether a sensory bracelet, which is already successfully being used to monitor women's fertility cycles, can detect Covid-19 infection early. If the virus is detected early on, patients can be isolated quickly and given targeted support. Early detection also makes it easier to protect healthcare professionals and manage the limited resources of healthcare systems more efficiently.

Más información aquí.



Vencer al Covid-19

Emerge, una aplicación de blockchain que ayuda a rastrear los casos de Covid-19

STARTUPS | Publicada el 14/04/2020

Emerge, una startup de blockchain con sede en Toronto, ha creado una aplicación de sistema de seguridad pública llamada Civitas. El objetivo de esta App es ayudar a las autoridades locales de distintas regiones, entre ellas América Latina, a combatir la pandemia del Coronavirus.



Más información aquí.

Vencer al Covid-19

La solución de telemedicina de Zerintia mejora el seguimiento médico de mayores y enfermos crónicos de Cataluña Central, confinados en casa durante la crisis del COVID.

STARTUPS | Publicada el 14/04/2020

Zerintia Technologies, junto a Vodafone y a la Fundación Universitaria del Bages, ponen en marcha un proyecto conjunto para ayudar a que mayores y enfermos crónicos con síntomas de COVID-19 de la zona de Cataluña Central, puedan ser atendidos por un servicio médico en remoto. Esta zona, cuenta con una gran dispersión geográfica y con un índice de envejecimiento más elevado que la media española, por lo que es una de las más necesitadas de ayuda en la actual situación de emergencia sanitaria.

Más información aquí.



Vencer al Covid-19

La startup israelita Diagnostic Robotics desarrolla plataforma con IA para monitorizar y predecir la epidemia del Covid-19

STARTUPS | Publicada el 14/04/2020

Israeli health officials are using a digital risk assessment and monitoring platform developed by Tel Aviv-based startup Diagnostic Robotics as part of their strategy to help track the spread of the coronavirus in Israel and assess their progress in bringing it under control. The Israeli Health Ministry has used Diagnostic Robotics' solution for remote screening since March, leveraging the platform to analyze a patient's clinical symptoms and underlying health status, generate a personalized risk profile for COVID-19, and provide next-step guidance. This is done through an opt-in, anonymous questionnaire sent via text message, to be answered every day. The questionnaire monitors symptoms while also minimizing direct contact with medical teams to ease the burden on already stretched healthcare staff. Sign up for our free weekly newsletter



Más información aquí.


Vencer al Covid-19

Coronavirus | Las startups impulsadas por Juan Roig reorientan sus negocios para luchar contra la covid-19

STARTUPS | Publicada el 07/04/2020

Los emprendedores del hub de emprendimiento Marina de Empresas —impulsado por Juan Roig y compuesto por EDEM Escuela de Empresarios, Lanzadera y Angels— han reaccionado a la crisis del coronavirus volcándose en la ayuda al sector sanitario. Muchas empresas han reorientado su actividad y producción para contribuir con productos y servicios a paliar los efectos de la pandemia en España. Las startups están colaborando con el sistema sanitario español a través de diferentes iniciativas. Las que ya trabajaban en servicios relacionados con la salud, como Quibim, HumanITcare o Serenmind, han adaptado sus plataformas y las han abierto para que los médicos o usuarios finales puedan hacer uso de las mismas de forma gratuita.

Más información aquí.



La Islandesa Sidekick crea una solución para el cuidado remoto de los pacientes de COVID-19

STARTUPS | Publicada el 06/04/2020

The Iceland-based digital health company Sidekick has adapted its technology to provide remote monitoring, triage and support for COVID-19 patients with the help of the Reykjavik-based computer games firm CCP. Sidekick is providing the country's emergency management authorities with a national COVID-19 programme to help manage infected individuals in their homes. The Sidekick COVID-19 programme is a CE-marked medical device allowing patients to self-report on a panel of symptoms and measurements on a predefined schedule several times a day if needed.

Más información aquí.


Vencer al Covid-19

¿Puede su teléfono inteligente detectar signos tempranos de infección por coronavirus?

STARTUPS | Publicada el 03/04/2020

As the government is criticised for its slow rollout of coronavirus testing, companies that make wearable tech are rushing to adapt their devices to detect Covid-19. In 2009, Fitbit released its first wearable device, a wristband that measured steps and estimated calories burned. This week, it unveiled the Fitbit Charge 4, a smart-watch that measures heart rate, senses the concentration of oxygen in the blood and tracks a user's runs via GPS.

[Más información aquí.](#)



Corona-tracker de Velmio

STARTUPS | Publicada el 02/04/2020

The ongoing COVID-19 outbreak has been characterized by mounting pressure on the healthcare system and a lack of real-time data sources for governments, businesses and individuals to monitor the situation. Digital health offers a natural solution for collecting data and delivering information in a timely manner. Corona-tracker by Velmio helps you log your symptoms and risk factors, to check in to the real-time map and monitor your risk and recovery. If you own a wearable device you have the option to automatically sync your data via Google Fit to provide researchers with additional context on your situation.

[Más información aquí.](#)

Vencer al Covid-19

NOTICIAS

La vacuna del COVID-19 de la Universidad de Oxford comienza la etapa de pruebas en humanos

NOTICIAS | Publicada el 24/04/2020

University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine. Of the first two volunteers to take part today, one will likewise receive the vaccine and the other the control. The researchers started screening healthy volunteers (aged 18-55) in March for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine is based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein, and has been produced in Oxford.



[Más información aquí.](#)

La farmacéutica Roche desarrolla la prueba de detección de anticuerpos COVID-19

NOTICIAS | Publicada el 22/04/2020

Pharmaceutical firm Roche said it has developed and would soon launch its test detecting antibodies in people exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes COVID-19. The Elecsys Anti-SARS-CoV-2 serology test can support priority screening of ... Read More » The post Pharmaceutical firm Roche develops COVID-19 antibodies detection test appeared first on Homeland Preparedness News.

[Más información aquí.](#)


Vencer al Covid-19

El CSIC lanza un estudio genético para identificar el riesgo individual de desarrollar formas graves de Covid-19

NOTICIAS | Publicada el 22/04/2020

El trabajo busca determinar las causas genéticas de que algunos infectados no sufran afectación clínica mientras que otros padecen reacciones muy adversas a la enfermedad. Investigadores del Consejo Superior de Investigaciones Científicas (CSIC) han puesto en marcha un estudio genético para identificar el riesgo individual de desarrollar formas graves de Covid-19. Los resultados podrían ayudar a prevenir infecciones graves y a descubrir potenciales tratamientos.

[Más información aquí.](#)




Vencer al Covid-19

Científicos de todo el mundo trabajan en 115 posibles vacunas para el COVID-19

NOTICIAS | Publicada el 21/04/2020

Public, private and philanthropic organisations are putting staggering R&D resources into the fight against COVID-19, with at least 115 vaccines in development. The tally, visualised above by the Wellcome Trust, was made by the Coalition for Epidemic Preparedness Innovations (CEPI), which is funding eight vaccine efforts. The research was published in Nature Reviews Drug Discovery, a journal on drug development. There are other tallies out there: the Austrian Institute for Health Technology Assessment for example counts 155 test vaccines in development. Five candidates have recently moved into clinical development, including test vaccines by US-based companies Moderna and Inovio, and China's CanSino Biologicals and Shenzhen Geno-Immune Medical Institute.

[Más información aquí.](#)



Vencer al Covid-19

Grifols dice que las inmunoglobinas hiperinmunes contra el coronavirus podrían estar listas a mediados de julio

NOTICIAS | Publicada el 21/04/2020

BARCELONA — Spanish pharmaceutical company Grifols said on Tuesday the hyperimmune immunoglobins it is developing as a treatment against SARS-COV-2 could be ready in mid-July. The Barcelona-based company also said it is producing a test device to detect the coronavirus, which it expects to be ready in early May as its plasma centres and industrial and commercial sites remain operational amid the global health crisis. SARS-CoV-2 is the formal name for the coronavirus. Grifols announced first quarter results in which it posted an 8% year-to-year net profit rise of 186.4 million euros (\$202 million). Its net sales grew to 1.29 billion euros (\$1.40 billion) versus 1.16 billion euros a year ago. The company said it was taking measures to strengthen its liquidity during the crisis, adding it was confident in its long-term growth strategy.

[Más información aquí.](#)

Vencer al Covid-19

¿Tienen las personas vacunadas con BCG alguna ventaja de inmunidad sobre las personas no vacunadas?

NOTICIAS | Publicada el 21/04/2020

Second Installment of Preliminary Interrogation by Patricio V. Marquez, Albert Figueras, Allison Ross, Giovanni S. Marquez, and Jaime Bayona "...government and municipal officials were putting their heads together. So long as each individual doctor has come across only two or three cases, not one had thought of taking action. But it was merely a matter of adding up the figures and, once this had been done, the total was startling. In a very few days the number of cases had risen by leaps and bounds, and it became evident to all observers of this strange malady that a real epidemic had set in." Albert Camus, The Plague, 1947



[Más información aquí.](#)

SOM Biotech anuncia la confirmación in vitro de tres candidatos a fármacos para COVID-19 en colaboración con la Universidad EwhaWomans

NOTICIAS | Publicada el 20/04/2020

SOM Biotech announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19. The three candidates inhibit the main protease of SARS-CoV-2 and therefore the replication of the virus. Clinical studies with the three candidates can be initiated immediately. SOM Biotech has applied its artificial intelligence-based screening technology (SOMAIPRO) to identify inhibitors of the 3CL proteases of SARS-CoV-2, SARS-CoV and MERS-CoV viruses as potential candidates to treat COVID-19. The discoveries came as a result of the research conducted jointly by SOM Biotech and the Department of Pharmacy and Pharmaceutical Sciences led by Professor Dong-Hae Shin from Ewha Womans University in South Korea.

[Más información aquí.](#)

Vencer al Covid-19

IVI, INOVIO y KNIH se asociarán con CEPI en la fase 1/2 del ensayo clínico de la vacuna de ADN COVID-19 de INOVIO en Corea del Sur

NOTICIAS | Publicada el 16/04/2020

PLYMOUTH MEETING, Pa. and SEOUL, South Korea, April 16, 2020 /PRNewswire/ -- The International Vaccine Institute (IVI) announced today that the Coalition for Epidemic Preparedness Innovations (CEPI) has granted \$6.9 million funding to INOVIO (NASDAQ:INO) to work with IVI and the Korea National Institute of Health (KNIH) for a Phase 1/2 clinical trial of INOVIO's COVID-19 vaccine candidate (INO-4800) in South Korea. IVI will conduct the trial in parallel to INOVIO's Phase 1 INO-4800 study currently underway in the US since April 6, 2020 with 40 healthy adults receiving the vaccine candidate and eventually expanding to older adults.

[Más información aquí.](#)

Moderna: Timeline de nuestra respuesta a día 16 de 2020

NOTICIAS | Publicada el 16/04/2020

Moderna is proud to be among the many groups working to respond to this continuing global health emergency. This page summarizes key milestones in our work to advance our vaccine candidate (mRNA-1273) and responds to frequently asked questions. On April 16, 2020, Moderna announced an award from U.S. government agency BARDA for up to \$483 million to accelerate development of mRNA-1273. This award will fund the development of mRNA-1273 to FDA licensure and manufacturing process scale-up to enable large-scale production in 2020 for pandemic response. Moderna plans to hire 150 new team members to support these efforts. Moderna also announced that the NIH-led Phase 1 study of mRNA-1273 has completed enrollment of three dose cohorts (25 µg, 100 µg and 250 µg) and is expanding to an additional six cohorts of older adults and elderly adults.

[Más información aquí.](#)


Vencer al Covid-19

Sanofi y GSK unirán fuerzas en una colaboración de vacunas sin precedentes para luchar contra COVID-19

NOTICIAS | Publicada el 14/04/2020

Sanofi and GSK today announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic. Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi's licensed recombinant influenza product in the US.

[Más información aquí.](#)



Vencer al virus: más de 160 candidatos a fármacos y vacunas COVID-19 en desarrollo

NOTICIAS | Publicada el 13/04/2020

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—"What do you have to lose?" he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader menu of therapeutic options. In all, the tally of vaccines and treatments in development against COVID-19 as of April 13 was at least 161 candidates—more than double the 60 candidates highlighted in GEN's previous A-List summarizing therapies in the works against SARS-CoV-2, *Catching Up to Coronavirus: Top 60 Treatments in Development*.

[Más información aquí.](#)

Vencer al Covid-19

Carta abierta del CEO de Gilead

NOTICIAS | Publicada el 10/04/2020

Earlier today, the New England Journal of Medicine (NEJM) published an analysis of the effects of our investigational medicine remdesivir on a small group of patients with severe symptoms of COVID-19. These are patients who received treatment through the compassionate use program for remdesivir, which is for critically ill patients who are unable to take part in a clinical trial. The results, which cover 53 of the first patients to have been treated in the program, show that the majority demonstrated clinical improvement after taking remdesivir. We recognize the limitations of these compassionate use data from a purely investigational perspective, while knowing they are of the greatest significance for the patients whose symptoms improved. These early data from 53 patients have not been generated in a clinical trial and cover only a small portion of the critically ill patients who have been treated with remdesivir.

[Más información aquí.](#)



Michelin y otras compañías en la región francesa de Auvergne-Rhône-Alpes se unen para combatir la pandemia de COVID-19 mediante la fabricación de una máscara facial reutilizable

NOTICIAS | Publicada el 08/04/2020

Since March 16, a collaborative ecosystem¹ formed and coordinated by the Grenoble-based collective VOC-COV has been working on the design and large-scale rollout of a reusable mask. The OCOV® mask, entirely developed and manufactured in France's Auvergne-Rhône-Alpes region in record time, is affordable, sustainable and can be produced in large quantities. As opposed to an FFP1 or FFP2 face filter, made solely of filtering material, the OCOV® is an FMP1 or FMP2 face mask featuring a flexible facepiece covering the nose, mouth and chin, as well as replaceable and reusable filters.

[Más información aquí.](#)